AbbVie Inc.(ABBV) (Q4FY23) – Biosimilar headwinds comes with biologics expansion

Highlights of the report

AbbVie’s flagship product, Humira, experienced a substantial operational revenue decline of 40.7% globally, with a full-year decrease of 31.9%.

AbbVie (ABBV) Equity Report Q4FY23

CrispIdea equity reports provide valuable insights to investors who may be individuals and organizations involved in the world of finance and investment like private equity houses, broking firms, hedge funds, investment advisory firms, mutual funds, banks and corporations. This research report is useful for M&A, business & investment analysis to all students and researchers also.


CrispIdea equity reports include basic financials, strategic analysis, competitive landscape assessments, stock performance, stock analysis and future growth potential evaluation. CrispIdea utilizes a proprietary blend of fundamental and technical analysis, offering a unique perspective. Reports present clear investment recommendations (“BUY,” “HOLD,” or “SELL”).


Our established reputation and track record advocates that our research carries weight within the investment community. Do connect with us, if you are looking for customized research, equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune.

While ABBV posted decreasing in revenue of $14.30bn in Q4FY23 compared to last year’s Q4FY22 of $15.12bn. On the surface, revenue decreased by (5%). Operating income decreased to $5.50bn in Q4FY23 from $1.83bn in Q4FY22. Net income increased massively to $822mn in Q4FY23 from $2.47bn in Q4FY22.

Over the last 3 months AbbVie stock has generated positive return of 22.36%, the price of stock has increased to $181.06 as on 6th March 2024 from $147.97 on 7th Dec 2023.



– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Metrics
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance


Stock Price Performance

Crispidea Coverage

Report details

AbbVie Inc.(ABBV) (Q4FY23) – Biosimilar headwinds comes with biologics expansion



Company Reports

Sector Reports